Yoshindo Pharmaceuticals, Toyama, announces foundation of joint venture for biosimilars with India’s Lupin Ltd

The new company, YL Biologics, Tokyo, will develop biosimilars such as Embrel (Etanercept), an anti-TNF used as antirheumatic agent.

Yoshindo Pharmaceuticals news release, April 24, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny